Lonidamine

Lonidamine

SCHEMBL29351122

O=C(O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2D6 P10635 1/20 1.00
TSHR P16473 1/20 1.00
PMP22 Q01453 1/20 1.00
HIF1A Q16665 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
PTGER4 P35408 4/20 0.52
SLC9A1 P19634 1/20 0.51
LMNA P02545 4/20 0.51
ALDH1A1 P00352 3/20 0.51
MAPT P10636 2/20 0.51
ALOX12 P18054 1/20 0.51
NPC1 O15118 1/20 0.51
MCL1 Q07820 1/20 0.47
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
PTGER1 P34995 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lonidamine SCHEMBL29350056 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
Lonidamine SCHEMBL7134 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
Lonidamine SCHEMBL28075715 0.93 CYP1A2 (0.87) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
Lonidamine SCHEMBL28086501 0.92 CYP1A2 (0.85) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
Lonidamine SCHEMBL5483035 0.91 CYP1A2 (0.83) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
SCHEMBL31566279 0.90 CYP1A2 (0.82) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
SCHEMBL14584151 0.90 CYP1A2 (0.82) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
SCHEMBL21121979 0.90 CYP1A2 (0.82) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
SCHEMBL30949037 0.90 CYP1A2 (0.81) CYP1A2CYP3A4CYP2C9CYP2D6TSHR
SCHEMBL1051466 0.90 CYP1A2 (0.81) CYP1A2CYP3A4CYP2C9CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624020-B2 Compositions and methods for preparing and using azetidines UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-05-12 US claimed
EP-4040487-B1 DISPLAY DEVICE SAMSUNG DISPLAY CO LTD (KR) 2026-01-21 EP claimed
EP-3181125-B1 CAPSULE FORMULATION CAPSUGEL BELGIUM NV (BE) 2025-02-19 EP claimed
CN-118397172-A CT image STL three-dimensional reconstruction method and device based on U-Net 湖北英库科技有限公司 2024-07-26 CN claimed
CN-113552441-B Single-phase earth fault detection method and device 南京南瑞继保电气有限公司 2024-04-30 CN claimed
CN-117241818-A Combination therapy of amuc_1100 and immune checkpoint modulator for the treatment of cancer 和度生物技术(上海)有限公司 2023-12-15 CN claimed
EP-4277659-A1 COMBINATION THERAPIES OF AMUC_1100 AND IMMUNE CHECKPOINT MODULATORS FOR USE IN TREATING CANCERS Commbio Therapeutics Co., Ltd. (CN) 2023-11-22 EP claimed
CN-113845478-B Intermediate, and preparation method and application thereof 四川大学 2023-11-21 CN claimed
CN-116731072-A Lonidamine prodrug compound, preparation method and application thereof 中国海洋大学 2023-09-12 CN claimed
WO-2023096206-A1 METHOD FOR PREPARING URETHANE-BASED PREPOLYMER 수경화학 주식회사 2023-06-01 WO claimed
CN-116056690-A Compositions and methods for the treatment and prevention of coronavirus infections 新概念医疗有限公司 2023-05-02 CN claimed
US-20230121082-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-04-20 US claimed
US-11512072-B2 Compositions and methods for preparing and using azetidines UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-11-29 US claimed
WO-2022169248-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR 주식회사 엘지화학 2022-08-11 WO claimed
WO-2022127805-A1 COMBINATION THERAPIES OF AMUC_1100 AND IMMUNE CHECKPOINT MODULATORS FOR USE IN TREATING CANCERS COMMBIO THERAPEUTICS CO., LTD. (CN) 2022-06-23 WO claimed
CN-112058237-B Preparation method of chiral metal organic framework material and application of chiral metal organic framework material in tetracycline hydrochloride sustained release 蚌埠学院 2022-06-17 CN claimed
WO-2022092490-A1 COOLING LIQUID COMPOSITION FOR ELECTRIC VEHICLE 주식회사 케이디파인켐 2022-05-05 WO claimed
EP-4744676-A2 BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA Synlogic Operating Company, Inc. (US) 2026-05-20 EP disclosed
CN-113967267-A Endoplasmic reticulum targeting of fatty acid modified albumin and uses thereof 四川大学 2022-01-25 CN disclosed
CN-106250402-B Website classification method and device 新华三技术有限公司 2022-01-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512072-B2 Compositions and methods for preparing and using azetidines DGKA, DGKK, PRKG2 CYP1A2 2261/4885CYP3A4 2854/4885CYP2C9 1115/4885
US-12624020-B2 Compositions and methods for preparing and using azetidines PRKAR2A, GRK2, GRK6 CYP1A2 2660/4885CYP3A4 3051/4885CYP2C9 1730/4885
US-20230121082-A1 COMPOSITIONS AND METHODS FOR PREPARING AND USING AZETIDINES DGKA, DGKK, PRKG2 CYP1A2 2261/4885CYP3A4 2854/4885CYP2C9 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.